Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma

Nature Medicine

Volumn 21, Issue 8, 2015, Pages 946-954

  Nassar, Dany ^a   Latil, Mathilde ^a   Boeckx, Bram ^b,c   Lambrechts, Diether ^b,c   Blanpain, Cédric ^a,d  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d WELBIO   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CARCINOGEN; K RAS PROTEIN; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CHROMOSOME ABERRATION; CONTROLLED STUDY; EXOME; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOMICS; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MOUSE; MUTANT; NONHUMAN; ONCOGENE H RAS; PAPILLOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; ANIMAL; CHEMICALLY INDUCED; CLONAL EVOLUTION; GENETICS; MUTATION; ONCOGENE RAS; PATHOLOGY; SKIN TUMOR;

MUS;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CLONAL EVOLUTION; EXOME; FEMALE; GENES, RAS; GENOMICS; HUMANS; MICE; MUTATION; SKIN NEOPLASMS;

EID: 84938770070     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3878     Document Type: Article

References (70)

1. Luch, A. Nature and nurture -lessons from chemical carcinogenesis. Nat. Rev. Cancer 5, 113-125 (2005).
2. Poirier, M.C. Chemical-induced DNA damage and human cancer risk. Nat. Rev. Cancer 4, 630-637 (2004).
3. Abel, E.L., Angel, J.M., Kiguchi, K. & DiGiovanni, J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat. Protoc. 4, 1350-1362 (2009).
4. Balmain, A., Ramsden, M., Bowden, G.T. & Smith, J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 307, 658-660 (1984).
5. Quintanilla, M., Brown, K., Ramsden, M. & Balmain, A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322, 78-80 (1986).
6. Bizub, D., Wood, A.W. & Skalka, A.M. Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc. Natl. Acad. Sci. USA 83, 6048-6052 (1986).
7. Ruggeri, B. et al. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res. 51, 6615-6621 (1991).
8. Kemp, C.J., Donehower, L.A., Bradley, A. & Balmain, A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74, 813-822 (1993).
9. Aldaz, C.M., Trono, D., Larcher, F., Slaga, T.J. & Conti, C.J. Sequential trisomization of chromosomes 6 and 7 in mouse skin premalignant lesions. Mol. Carcinog. 2, 22-26 (1989).
10. Quigley, D.A. et al. Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biol. 12, R5 (2011).
11. Lapouge, G. et al. Identifying the cellular origin of squamous skin tumors. Proc. Natl. Acad. Sci. USA 108, 7431-7436 (2011).
12. White, A.C. et al. Defining the origins of Ras/p53-mediated squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 108, 7425-7430 (2011).
13. Beck, B. et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478, 399-403 (2011).
14. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
15. Dipple, A., Pigott, M., Moschel, R.C. & Costantino, N. Evidence that binding of 7, 12-dimethylbenz(a)anthracene to DNA in mouse embryo cell cultures results in extensive substitution of both adenine and guanine residues. Cancer Res. 43, 4132-4135 (1983).
16. Cai, Y., Patel, D.J., Broyde, S. & Geacintov, N.E. Base sequence context effects on nucleotide excision repair. J. Nucleic Acids 2010, 174252 (2010).
17. Westcott, P.M. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489-492 (2015).
18. Bos, J.L. ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689 (1989).
19. Saez, R., Chan, A.M., Miki, T. & Aaronson, S.A. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes. Oncogene 9, 2977-2982 (1994).
20. Schramek, D. et al. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science 343, 309-313 (2014).
21. Chu, W.K. & Hickson, I.D. RecQ helicases: multifunctional genome caretakers. Nat. Rev. Cancer 9, 644-654 (2009).
22. Nicolas, M. et al. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 33, 416-421 (2003).
23. Laczmanska, I. et al. Copy number alterations of chromosomal regions enclosing protein tyrosine phosphatase receptor-like genes in colorectal cancer. Pathol. Res. Pract. 210, 893-896 (2014).
24. Provost, E. et al. The tumor suppressor rpl36 restrains KRAS(G12V)-induced pancreatic cancer. Zebrafish 11, 551-559 (2014).
25. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576-582 (2015).
26. Cohen-Dvashi, H. et al. Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. EMBO Mol. Med. 7, 299-314 (2015).
27. Dickinson, R.E. et al. Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br. J. Cancer 91, 2071-2078 (2004).
28. Hase, K. et al. AP-1B-mediated protein sorting regulates polarity and proliferation of intestinal epithelial cells in mice. Gastroenterology 145, 625-635 (2013).
29. Yu, J. et al. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev. Cell 18, 288-299 (2010).
30. Pogue-Geile, K.L. et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 3, e516 (2006).
31. Lee, C.S. et al. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. Nat. Genet. 46, 1060-1062 (2014).
32. South, A.P. et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J. Invest. Dermatol. 134, 2630-2638 (2014).
33. Pickering, C.R. et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin. Cancer Res. 20, 6582-6592 (2014).
34. Li, Y.Y. et al. Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin. Cancer Res. 21, 1447-1456 (2015).
35. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
36. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
37. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
38. Song, Y. et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91-95 (2014).
39. Lin, D.C. et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat. Genet. 46, 467-473 (2014).
40. India Project Team of the International Cancer Genome Consortium. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrentlymutated genes and molecular subgroups. Nat. Commun. 4, 2873 (2013).
41. Ojesina, A.I. et al. Landscape of genomic alterations in cervical carcinomas. Nature 506, 371-375 (2014).
42. Lin, D.C. et al. The genomic landscape of nasopharyngeal carcinoma. Nat. Genet. 46, 866-871 (2014).
43. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
44. Wu, W. et al. HERC2 is an E3 ligase that targets BRCA1 for degradation. Cancer Res. 70, 6384-6392 (2010).
45. Toll, A. et al. MYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. Br. J. Dermatol. 161, 1112-1118 (2009).
46. Al Bashir, S. et al. Cysteine-rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients prognosis. J. Hematol. Oncol. 7, 21 (2014).
47. Quintana, R.M. et al. A transposon-based analysis of gene mutations related to skin cancer development. J. Invest. Dermatol. 133, 239-248 (2013).
48. McFadden, D.G. et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156, 1298-1311 (2014).
49. Dudgeon, C. et al. The evolution of thymic lymphomas in p53 knockout mice. Genes Dev. 28, 2613-2620 (2014).
50. Hennings, H. et al. FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 14, 2353-2358 (1993).
51. Lapouge, G. et al. Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness. EMBO J. 31, 4563-4575 (2012).
52. Miller, S.J. et al. Mouse skin is particularly susceptible to tumor initiation during early anagen of the hair cycle: possible involvement of hair follicle stem cells. J. Invest. Dermatol. 101, 591-594 (1993).
53. Blanpain, C., Lowry, W.E., Geoghegan, A., Polak, L. & Fuchs, E. Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 118, 635-648 (2004).
54. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
55. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
56. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
57. Albers, C.A. et al. Dindel: accurate indel calls from short-read data. Genome Res. 21, 961-973 (2011).
58. Quinlan, A.R. & Hall, I.M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841-842 (2010).
59. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
60. Dees, N.D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22, 1589-1598 (2012).
61. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
62. Farkash-Amar, S. et al. Global organization of replication time zones of the mouse genome. Genome Res. 18, 1562-1570 (2008).
63. Choi, Y., Sims, G.E., Murphy, S., Miller, J.R. & Chan, A.P. Predicting the functional effect of amino acid substitutions and indels. PLoS One 7, e46688 (2012).
64. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
65. Risso, D., Schwartz, K., Sherlock, G. & Dudoit, S. GC-content normalization for RNA-Seq data. BMC Bioinformatics 12, 480 (2011).
66. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
67. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
68. Wang, K. et al. PennCNV: an integrated hidden Markov model designed for highresolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 17, 1665-1674 (2007).
69. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 104, 20007-20012 (2007).
70. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).